About: Gene Expression of Somatostatin Receptor 4 Predicts Clinical Outcome of Patients with Metastatic Neuroendocrine Tumors Treated with Somatostatin Analogs

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Gene Expression of Somatostatin Receptor 4 Predicts Clinical Outcome of Patients with Metastatic Neuroendocrine Tumors Treated with Somatostatin Analogs Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	Somatostatin analogs (SSA) are the standard diagnostic and treatment tools in the clinical management of patients with neuroendocrine tumors (NETs) expressing somatostatin receptors (SSTRs). Although symptomatic and biochemical control is obtained with SSA in the majority of functional NETs, antineoplastic effects of SSA are partial and of limited duration. The aim of this study was to quantify expression levels of five SSTR subtypes (SSTR1-SSTR5) and correlate them with the clinical outcomes of patients with NETs who underwent SSA therapy. The expression levels were analyzed using real-time polymerase chain reaction in a series of 22 metastatic NETs with a median time of 10 months on the SSA therapy (range 2-82 months). The median duration of disease stabilization in patients who developed progression (n=14) was 9 months (range 3-92 months). The median survival period for all patients was 44 months (range 3-175 months). Somatostatin analogs (SSA) are the standard diagnostic and treatment tools in the clinical management of patients with neuroendocrine tumors (NETs) expressing somatostatin receptors (SSTRs). Although symptomatic and biochemical control is obtained with SSA in the majority of functional NETs, antineoplastic effects of SSA are partial and of limited duration. The aim of this study was to quantify expression levels of five SSTR subtypes (SSTR1-SSTR5) and correlate them with the clinical outcomes of patients with NETs who underwent SSA therapy. The expression levels were analyzed using real-time polymerase chain reaction in a series of 22 metastatic NETs with a median time of 10 months on the SSA therapy (range 2-82 months). The median duration of disease stabilization in patients who developed progression (n=14) was 9 months (range 3-92 months). The median survival period for all patients was 44 months (range 3-175 months). (en)
Title	Gene Expression of Somatostatin Receptor 4 Predicts Clinical Outcome of Patients with Metastatic Neuroendocrine Tumors Treated with Somatostatin Analogs Gene Expression of Somatostatin Receptor 4 Predicts Clinical Outcome of Patients with Metastatic Neuroendocrine Tumors Treated with Somatostatin Analogs (en)
skos:prefLabel	Gene Expression of Somatostatin Receptor 4 Predicts Clinical Outcome of Patients with Metastatic Neuroendocrine Tumors Treated with Somatostatin Analogs Gene Expression of Somatostatin Receptor 4 Predicts Clinical Outcome of Patients with Metastatic Neuroendocrine Tumors Treated with Somatostatin Analogs (en)
skos:notation	RIV/00216224:14110/10:00051807!RIV12-MSM-14110___
http://linked.open...avai/riv/aktivita	I Z
http://linked.open...avai/riv/aktivity	I, Z(MZ0MOU2005)
http://linked.open...iv/cisloPeriodika	2
http://linked.open...vai/riv/dodaniDat	2012
http://linked.open...aciTvurceVysledku	Slabý, Ondřej Šachlová, Milana Valík, Dalibor Vyzula, Rostislav Svoboda, Marek Fabian, Pavel Vytopilová, Simona Bednaříková, Markéta
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Masarykova univerzita / Lékařská fakulta
http://linked.open...dnocenehoVysledku	260304
http://linked.open...ai/riv/idVysledku	RIV/00216224:14110/10:00051807
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	carcinoid; neuroendocrine tumors; prognosis; response prediction; somatostatin analogs; somatostatin receptors (en)
http://linked.open.../riv/klicoveSlovo	carcinoid neuroendocrine tumors somatostatin analogs prognosis response prediction somatostatin receptors
http://linked.open...odStatuVydavatele	US - Spojené státy americké
http://linked.open...ontrolniKodProRIV	[D6AA655A3700]
http://linked.open...i/riv/nazevZdroje	Cancer Biotherapy and Radiopharmaceuticals
http://linked.open...in/vavai/riv/obor	FD
http://linked.open...ichTvurcuVysledku	8 (xsd:int)
http://linked.open...cetTvurcuVysledku	8 (xsd:int)
http://linked.open...UplatneniVysledku	2010
http://linked.open...v/svazekPeriodika	25
http://linked.open...iv/tvurceVysledku	Slabý, Ondřej Valík, Dalibor Šachlová, Milana Svoboda, Marek Vyzula, Rostislav Fabian, Pavel Bednaříková, Markéta Vytopilová, Simona
http://linked.open...ain/vavai/riv/wos	000277155900014
http://linked.open...n/vavai/riv/zamer	Functional diagnostics of malignant tumours
issn	1084-9785
number of pages	7 (xsd:int)
http://bibframe.org/vocab/doi	10.1089/cbr.2009.0708
http://localhost/t...ganizacniJednotka	14110

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 58 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software